





Review

Dual Role of Host Toll-Like Receptor 3 in Parasitic Diseases

Yixin Yang^{1,2}, Qilong Li^{1,2}, Yiwei Zhang^{1,2}, Ning Jiang^{1,2}, Qijun Chen^{1,2,*}

¹Key Laboratory of Livestock Infectious Diseases, Ministry of Education, Key Laboratory of Ruminant Infectious Disease Prevention and Control (East), Ministry of Agriculture and Rural Affairs, College of Animal Science and Veterinary Medicine, Shenyang Agricultural University, 110866 Shenyang, Liaoning, China

²Research Unit for Pathogenic Mechanisms of Zoonotic Parasites, Chinese Academy of Medical Sciences, Shenyang Agricultural University, 110866 Shenyang, Liaoning, China

*Correspondence: qijunchen759@syau.edu.cn (Qijun Chen)

Academic Editor: Agnieszka Paradowska-Gorycka

Submitted: 5 December 2024 Revised: 15 February 2025 Accepted: 24 February 2025 Published: 29 July 2025

Abstract

Parasitic diseases, caused by a diverse array of parasites, remain a substantial threat to global health. Toll-like receptor 3 (TLR3) represents a pivotal element in the innate immune system, distinguished by an ability to signal via the TIR-domain-containing adapter-inducing interferon- β (TRIF)-dependent pathway upon detecting pathogen-derived double-stranded RNA (dsRNA), exosomal RNA (exoRNA), and long non-coding RNA (lncRNA). Predominantly localized on endosomal membranes, TLR3 is extensively expressed in neurons, immune cells, fibroblasts, and epithelial cells. Upon activation, TLR3 engages adaptor molecules such as TRIF, facilitating the phosphorylation of TANK-binding kinase 1 and the subsequent activation of interferon regulatory factors. This signaling cascade triggers the production of type I interferons (IFN- α/β) and proinflammatory cytokines such as interleukin (IL)-6, IL-8, IL-12, and tumor necrosis factor-alpha, which are crucial for effective immune defense against infections. Recent findings highlight the essential role of TLR3 in parasitic infections by detecting nucleic acids from damaged cells to activate dendritic and natural killer cells. TLR3 also functions with other receptors, such as TLR2 and TLR4, to enhance cytokine production and improve parasite clearance. However, TLR3 overactivation can induce excessive, harmful inflammation and tissue damage, highlighting its dual role in balancing immune defense. This review comprehensively examines the TLR3 signaling pathway and its multifaceted role in various parasitic infections, including those caused by *Plasmodium* spp., *Leishmania* spp., *Clonorchis sinensis*, *Schistosoma japonicum*, *Trichinella spiralis*, and *Neospora caninum*.

Keywords: Toll-like receptor 3; parasitic disease; immune defense; inflammation

1. Introduction

Parasitic infections pose a substantial global health burden, affecting millions of individuals annually and causing significant morbidity and mortality, particularly among vulnerable populations such as children and pregnant women [1–4]. These infections are caused by a diverse range of pathogens, including *Plasmodium* spp., *Leishmania* spp., *Clonorchis sinensis*, *Schistosoma japonicum*, *Trichinella spiralis*, and *Neospora caninum* [5–10]. A key factor in the persistence and severity of these diseases is the ability of these parasites to evade host immune surveillance, ensuring their survival and replication within the host [11]. The host's innate and adaptive immune systems are critical for combating parasitic infections, maintaining immune homeostasis by recognizing and eliminating pathogens [12,13]. Among the pattern recognition receptors of the innate immune system, the Toll-like receptor (TLR) family plays a pivotal role in initiating immune responses upon detecting pathogen-associated molecular patterns [14,15]. TLRs activate downstream signaling pathways that lead to the production of cytokines and other inflammatory mediators essential for effective immune responses [16].

Toll-like receptor 3 (TLR3), a key member of the TLR family, uniquely signals through the TIR-domain-containing adapter-inducing interferon- β (TRIF) pathway [17]. Predominantly located on endosomal membranes, TLR3 is widely expressed in fibroblasts, epithelial cells, and various immune cells [18–24]. The intracellular region of TLR3 contains a TIR domain with two critical tyrosine residues. Upon recognition of viral double-stranded RNA (dsRNA) or activation by poly(I:C), TLR3 recruits TRIF and associated adaptor molecules, initiating downstream signaling cascades (Fig. 1) [25]. Activation of the TLR3–TRIF axis recruits TANK-binding kinase 1 (TBK1), leading to the activation and phosphorylation of interferon regulatory factors 3 and 7 (IRF3 and IRF7) [26]. Specifically, TBK1 and inhibitor of kappa B kinase epsilon (IKK- ϵ) regulate IRF3 activation. Phosphorylated IRF3 dimerizes, translocates into the nucleus, and induces the production of type I interferons (IFN- α/β) [27,28]. In parallel, downstream of TLR3–TRIF, tumor necrosis factor receptor-associated factor 6 (TRAF6) interacts with transforming growth factor- β (TGF- β)-activated kinase 1 (TAK1)-binding protein 2 (TAB2), leading to TAK1 autophosphorylation and activation. Activated TAK1 then stimulates the IKK complex, which comprises IKK- α and






Fig. 1. The signaling pathway of TLR3 in responses to double-stranded RNA (dsRNA). TLR3, located on endosomal membranes, recognizes dsRNA or the synthetic analog poly(I:C), thereby activating the TLR3 signaling pathway. The adaptor protein TRIF is recruited, which subsequently activates TRAF3 and TRAF6. TRAF3, in conjunction with TBK1 and IKK- ϵ , promotes the phosphorylation and nuclear translocation of IRF3/IRF7, leading to the production of type I interferons (IFN- α/β). These interferons enhance immune responses, activate natural killer (NK) cell cytotoxicity, and stimulate cytokine secretion. Simultaneously, TRAF6 interacts with TAK1 and TAB2 to activate the MAPK pathway, facilitating the phosphorylation and nuclear translocation of transcription factors AP-1 and NF- κ B. This cascade results in the production of pro-inflammatory cytokines, including IL-6, IL-8, IL-12, TNF- α , and IFN- γ . These cytokines play essential roles in immune cell activation, macrophage-mediated pathogen phagocytosis, and sustained NK cell functionality. Additionally, cross-regulation with other TLRs, such as TLR4 and TLR7, enhances immune responses and supports effective pathogen elimination. DsRNA, double-stranded RNA; TLR, Toll-like receptor; TRIF, TIR-domain-containing adapter-inducing interferon- β ; TRAF, tumor necrosis factor receptor-associated factor; TBK1, TANK-binding kinase 1; IKK, inhibitor of kappa B kinase; IRF, interferon regulatory factors; TAK1, transforming growth factor- β (TGF- β)-activated kinase 1; TAB2, TAK1-binding protein 2; MAPK, mitogen-activated protein kinase; IL, interleukin; TNF- α , tumor necrosis factor-alpha; NF- κ B, nuclear factor κ B; I κ B, inhibitor of NF- κ B; AP-1, activator protein-1; NEMO, NF- κ B essential modulator. Created with [BioRender.com](https://www.biorender.com).

IKK- β , via nuclear factor κ B (NF- κ B) essential modulator (NEMO; also known as IKK- γ), thereby activating NF- κ B or triggering mitogen-activated protein kinase (MAPK)-mediated activator protein-1 (AP-1) transcriptional responses [29]. As a result of TRIF-dependent sig-

naling, phosphorylated IRF3/7, NF- κ B, and AP-1 translocate to the nucleus, inducing the expression of IFN- α/β , IFN- γ , and pro-inflammatory cytokines, including interleukin (IL) -6, IL-8, IL-12, and tumor necrosis factor-alpha (TNF- α) [17,30–32]. This production of IFN-I and pro-

inflammatory cytokines following TLR3 activation is critical for host defense against pathogenic infections [33,34]. IFN-I plays a pivotal role in modulating immune responses by activating natural killer (NK) cell cytotoxicity and cytokine production via the interferon-alpha/beta receptor (IFNAR). This mechanism is particularly prominent during viral infections, where IFN-I protects NK cells from cytotoxic agents, supporting their expansion and functionality [35]. Furthermore, IFN- γ enhances macrophage phagocytic activity and pathogen clearance by regulating intracellular copper levels in phagosomes and by modulating cellular metabolism and mRNA translation to activate macrophages [36,37]. IL-12 stimulates NK cell activity and promotes IFN- γ production, while IL-6 enhances macrophage function and inflammatory responses [38,39]. TNF- α , induced through TLR3 signaling, directly activates macrophages and boosts NK cell effector functions [40]. Importantly, macrophages activated by TLR3 secrete IL-12 and TNF- α , creating a positive feedback loop that amplifies immune responses [41]. While TLR3 is essential for mediating innate immune responses and enhancing protective immunity, its activation can, under certain conditions, contribute to excessive inflammation, leading to collateral tissue damage [42,43]. This highlights the dual regulatory effects of TLR3, balancing effective immune defense with the risk of excessive inflammation. Furthermore, synergistic interactions between TLR3 and other TLRs, such as TLR2 and TLR4, can amplify immune cell activation, cytokine production, and parasite clearance [44]. It is noteworthy that TLR3 plays a critical role not only in antiviral immunity (e.g., COVID-19) but also in parasitic infections [29,44–50]. This activation results in the production of IFN- α/β and pro-inflammatory cytokines such as IL-6, IL-8, IL-12, and TNF- α , which are crucial for mounting effective immune responses against parasitic invasions [17,30–32]. Therefore, understanding the intricate signaling pathways and regulatory mechanisms of TLR3 in parasitic infections is essential for developing novel therapeutic strategies aimed at enhancing host immunity while minimizing detrimental inflammation.

The present review provides a comprehensive overview of the TLR3 signaling pathway and its critical role in various parasitic infections. It aims to identify potential targets for immunotherapy and vaccine development to improve host resistance and global health outcomes.

2. Mechanisms of TLR3 in Parasitic Infections

In parasitic infections, the timely recognition and activation of the host immune system are critical for regulating parasite proliferation and determining disease outcomes. Emerging evidence underscores the indispensable role of TLR3 in the recognition and regulation of parasitic infections [8,46,47,51,52]. TLR3 can mediate immune responses to parasitic infections through several distinct

mechanisms. Parasite-derived nucleic acids are recognized by TLR3, which then activates downstream immune signaling pathways and induces a strong pro-inflammatory response [22,37,53]. This immune activation not only aids in parasite clearance but also regulates immune homeostasis [36]. The first mechanism involves TLR3 recognizing parasite-derived exoRNA released from damaged host cells, promoting cytokine secretion, and enhancing host defense, which is critical for initiating an effective immune response against parasitic infections. The second mechanism is the regulation of immune cell functions by TLR3, which involves regulating dendritic cells (DCs) and NK cells, boosting their activity, and enhancing the host's resistance to parasites. The third mechanism is the synergistic action of TLR3 with other TLRs, which amplifies immune responses by interacting with these receptors to enhance immune signaling, ultimately facilitating more effective parasite clearance. Understanding these mechanisms is essential for elucidating immune regulation in host-parasite interactions and developing related immunotherapies. These mechanisms will be further elaborated in the subsequent sections of the review.

Once exoRNA released by host cells damaged during parasitic infections is recognized by TLR3, an immune response is initiated [22,38]. Based on current experimental evidence, TLR3 may recognize parasite-derived extracellular RNA during malaria infection, thereby triggering an immune response in the host. This recognition induces the production of significant levels of pro-inflammatory cytokines, including IFN- β , IFN- γ , and TNF- α , through activation of the downstream IRF3 and NF- κ B signaling pathways [46]. These cytokines, in turn, activate immune cells such as macrophages and NK cells, enhancing their cytotoxic activity and contributing to the host's control of parasitic infection [39]. Pre-stimulation of human and mouse neurons with IFN- γ enhances the activity of immunity-related GTPases, which target and disrupt the parasitophorous vacuole that shelters intracellular parasites. This disruption effectively inhibits the proliferation of *Toxoplasma gondii* [41]. Moreover, IFN- γ is a pleiotropic cytokine with diverse immunomodulatory effects; it enhances erythropoiesis, upregulates MHC-I expression, and promotes the presentation of endogenous antigens by infected host cells. These effects enhance the susceptibility of infected cells to cytotoxic T lymphocytes, aiding in the clearance of *Plasmodium yoelii* 17XNL from the host [54,55].

Another crucial role of TLR3 in parasitic infections is the modulation of host immune cell functions [36]. Activation of TLR3 by pretreatment with the agonist poly(I:C) in *Leishmania* infections promotes a T helper 1 (Th₁)-type immune response and enhances antigen presentation, thereby improving host resistance to the parasite [56]. Similar observations have been reported in *Plasmodium falciparum*-infected BALB/c mice, where poly(I:C) pretreatment ac-

tivates TLR3, enhances the Th₁ response, and induces elevated IgG antibody levels as well as IFN- γ production, effectively mitigating severe symptoms of malaria infection [57,58]. TLR3 also plays a significant role in *Schistosoma mansoni* (*S. mansoni*) infections. The recognition of *S. mansoni* eggs by host TLR3 present on DCs leads to the expression of IFN-I, induction of interferon-stimulated genes (ISGs), and phosphorylation of signal transducer and activator of transcription 1 (STAT1), ultimately resulting in NF- κ B and IFN- β expression [59]. Moreover, TLR3 regulates the activity of NK cells during malaria and it seems to inhibit the activity of NK cells in the early stage of *Plasmodium* infection, which is beneficial for parasite infection [46]. The importance of NK cells in parasitic defense has been increasingly recognized, with TLR3 activation not only enhancing the cytotoxic capabilities of these cells but also modulating the functions of other immune cells via cytokine secretion [60].

TLR3 plays a crucial role in maintaining host immune homeostasis, while also enhancing immune responses through interactions with other TLRs, thereby amplifying overall immune activity [61]. During parasitic infections, cross-regulation between TLR3 and other TLRs, such as TLR2, TLR4, and TLR7, is essential for orchestrating an effective immune response. In *Schistosoma japonicum* (*S. japonicum*) infections, these TLRs contribute to the activation of T, B, NK, and $\gamma\delta$ T cells, synergistically promoting IFN- γ secretion, which drives the inflammatory response [60]. In *Neospora caninum* (*N. caninum*) infections, TLR3 and TLR2 collaborate to enhance IL-12p40 production, mitigating the pathogen's threat to the host. This synergy not only boosts antigen presentation by macrophages and DCs but also significantly upregulates the production of pro-inflammatory cytokines, such as IFN- γ and IL-12p40, through co-activation of the Myeloid differentiation primary response gene 88 (MyD88) and TRIF signaling pathways. This coordinated signaling facilitates the initiation of adaptive immunity and enhances T and B cell activation and proliferation, ultimately aiding the host immune system in controlling *N. caninum* proliferation [51]. TLR3 cooperates with other TLRs, such as TLR2, TLR4, and TLR7, to mount a robust and finely tuned immune response. Recent evidence suggests that TLR3-driven responses can synergize with MyD88-dependent signals triggered by other TLRs, enhancing the production of pro-inflammatory cytokines crucial for controlling intracellular pathogens and protozoan parasites [60,61]. For instance, during *N. caninum* infections, TLR2-mediated MyD88 activation cooperates with TLR3-TRIF signaling to increase IL-12p40 production, thereby effectively orchestrating downstream IFN- γ synthesis and macrophage activation [51]. This interaction not only promotes Th₁ immune responses but also amplifies the overall magnitude of adaptive immunity, enhancing T and B cell proliferation and improving pathogen clearance.

In *S. japonicum* infections, TLR2, TLR3, TLR4, and TLR7 cooperate in a tissue-specific manner, particularly within pulmonary lymphocytes, to boost IFN- γ production from T, B, NK, and $\gamma\delta$ T cells, ultimately reinforcing the protective inflammatory response [60]. Beyond these well-established synergistic roles, emerging research underscores an additional layer of complexity, whereby TLR3 can confer a form of “innate immune memory” that potentiates subsequent responses to TLR7 ligands and vice versa [61]. This crosstalk may be mediated by shared transcription factors and signaling intermediates, resulting in upregulated expression of crucial immune mediators, such as IFN- α/β , IL-6, and TNF- α , upon re-stimulation [61,62]. By facilitating reciprocal activation loops between MyD88- and TRIF-dependent pathways, TLR3 helps maintain a heightened state of readiness in innate immune cells, enabling the host to respond more rapidly and effectively to re-infection or secondary parasitic insults [61,63,64]. Furthermore, studies have shown that TLR3, TLR2, and TLR7 synergistically activate distinct signaling pathways to enhance pathogen phagocytosis and clearance by host cells [60,65]. TLR3 regulates autophagy-related genes through the TRIF pathway, while TLR2 and TLR7 release pro-inflammatory cytokines (such as IFN- β , TNF- α , and IL-6) via the MyD88 pathway. This coordinated action plays a crucial role in promoting *Trypanosoma cruzi* (*T. cruzi*) clearance, inhibiting *T. cruzi* growth, and establishing an effective immune response [65]. This integrated response, which involves the orchestrated activation of multiple TLRs, thus represents a promising target for next-generation vaccine adjuvants and immunotherapeutic interventions aimed at combating persistent or resistant parasitic infections.

Investigating the temporal dynamics of TLR3 activation and its interplay with other innate immune receptors could significantly advance our understanding of immune homeostasis in the context of persistent parasitic infections. A more profound understanding of the role of TLR may guide the development of innovative vaccine adjuvants, immune modulators, and therapeutic strategies, ultimately improving clinical outcomes for patients suffering from parasitic diseases. Through such targeted investigations, we can move closer to a paradigm in which immune-based therapies can effectively eradicate parasitic infections while minimizing adverse effects, thereby addressing a critical unmet need in global health.

3. TLR3 Signaling Pathway in Parasitic Infections

TLR3 recognizes exoRNA, long non-coding RNA (lncRNA), or poly(I:C) produced by damaged cells in response to parasitic infections (Fig. 2) to initiate immune responses [22,37,66–68]. TLR3 activates multiple transcription factors, such as IRF3, IRF7, and NF- κ B, in parasitic infections [63,69–71]. There are two primary pathways downstream of TLR3 activation. In the first pathway, TLR3




Fig. 2. Signaling pathway of TLR3 in parasite infection. TLR3 recognizes activation of exoRNA, lncRNA or poly(I:C) produced by damaged cells induced by parasite infection and generates various immune responses. Upon activation of TLR3, recruitment of TRIF occurs, which initiates signal transduction through its TIR. This activation subsequently leads to activation of the serine/threonine kinase TBK1, which then phosphorylates IRF3/IRF7. Another pathway of TLR3-TRIF is the recruitment of TAB2 via TRAF6 leading to phosphorylation and activation of TAK1 itself. Phosphorylated TAK1 stimulates IKK via NEMO, which in turn activates NF-κB to initiate IFN-γ transcription and promote IL-10 secretion. These transcription factors promote the production of pro-inflammatory signaling proteins such as TNF-α, IFN-γ and IFN-β. In general, activation of the TLR3 signaling pathway leads to the production of cytokines such as TNF-α, IFN-α/β, IFN-γ, IL-10 and IL-12. Created with BioRender.com.

activation leads to the recruitment of TRIF, which initiates signal transduction via its TIR domain. This in turn activates the serine/threonine kinase TBK1, which then phosphorylates IRF3 and IRF7 [72,73]. The phosphorylation of these transcription factors results in their nuclear translo-

cation, ultimately inducing the transcription of IFN-α/β [74,75]. The second major TLR3-TRIF pathway involves the recruitment of TAB2 via TRAF6, resulting in the phosphorylation and activation of TAK1. Phosphorylated TAK1 stimulates the IKK complex via NEMO, which in turn acti-

vates NF- κ B, promoting IFN- γ transcription and IL-10 secretion [17,76–78]. These transcription factors facilitate the production of pro-inflammatory cytokines, such as TNF- α , IFN- γ , and IFN- β [79]. Although TLR3 plays a critical role in host responses to parasitic infections, variations among different parasites may lead to diverse outcomes in infected hosts.

4. Research Progress on TLR3 and Different Parasites

4.1 Inhibitory Effect of TLR3 on the Blood Stage of Infection With *Plasmodium yoelii yoelii* 265 BY

Malaria is caused by *Plasmodium* species, which are transmitted to vertebrates through the bite of female *Anopheles* mosquitoes [5,80,81]. *Plasmodium* infects hundreds of millions of people with malaria each year, with the vast majority of severe malaria cases concentrated in African countries, particularly Nigeria, the Democratic Republic of the Congo, Niger, and the United Republic of Tanzania [82]. Patients with malaria usually exhibit symptoms such as fever, chills, and acute anemia. In severe cases, malaria can be fatal, causing hundreds of thousands of deaths each year, with children and pregnant women being particularly vulnerable, making it a significant health threat [80,83].

Understanding the interplay between TLR3 and immune responses is crucial for elucidating the mechanisms through which the host combats *Plasmodium* infection. Notably, TLR3 plays a key role in regulating *Plasmodium* infection [46]. In wild-type (WT) mice, activation of the TLR3-TRIF signaling axis induces the nuclear translocation of phosphorylated IRF3 and IRF7, triggering an early surge of pro-inflammatory cytokines such as IFN- γ , TNF- α , and IL-6 [72–75,79]. While these cytokines are essential for initiating immune responses, their sustained elevation results in detrimental inflammation [84]. In contrast, TLR3-knockout mice display a more balanced cytokine profile, characterized by diminished levels of pro-inflammatory mediators and increased production of the anti-inflammatory cytokine IL-10. This profile enhances parasite clearance and attenuates excessive immunopathology [85,86]. Further research indicates that, in the spleens of WT mice, TLR3 signaling appears to inhibit NK and NKT cell activity, delaying the initial immune response and allowing the parasite to establish infection [87–89]. This early activation of innate immune cells may contribute to a more rapid reduction of parasitemia in TLR3-knockout mice. During *Plasmodium yoelii yoelii* 265 BY (*P. yoelii yoelii* 265 BY) infection, TLR3-knockout mice exhibit enhanced T and B cell responses compared to WT mice. Specifically, the frequency and activation of CD4⁺ and CD8⁺ T cells are significantly higher in TLR3-knockout mice at the later stages of infection than in WT mice, suggesting a more robust adaptive immune response. In WT mice, TLR3 signaling inhibits the T cell response, poten-

tially facilitating parasite survival. In contrast, in TLR3-knockout mice, the absence of TLR3 signaling in B cells leads to a higher frequency of CD19⁺ cells and increased production of parasite-specific IgG. As depicted in Fig. 3a, after infection with *Plasmodium*, the TLR3 pathway is activated, leading to the production of IFN- γ and IL-12. This, in turn, can result in a decrease in IgG secretion by CD19⁺ TLR3⁺ B cells, thereby favoring parasite survival. This enhanced humoral response is likely a key factor in the improved parasite clearance observed in TLR3-knockout mice compared to WT mice. Notably, the proportion of CD19⁺ TLR3⁺ cells is significantly higher in the B cell population of C57 mice, potentially accounting for the delayed clearance of parasites during the erythrocytic cycle in these mice. This surge in parasite-specific antibodies was also observed to correlate with an increase in B cell numbers and enhanced parasitemia clearance. As presented in Table 1 (Ref. [8,43,44,46,47,52,90,91]), TLR3-knockout mice display an increase in total IgG, concurrent with an elevated proportion of CD19⁺ B cells and enhanced production of parasite-specific antibodies during *P. yoelii yoelii* 265 BY infection. Moreover, IgG production is inhibited in WT mice, suggesting a role for TLR3 in regulating the adaptive immune response [46]. These findings underscore the intricate regulatory function of TLR3 in orchestrating both erythrocytic and extra-erythrocytic immune phases during *Plasmodium* infection. Overall, these data highlight the potential of strategically targeting the TLR3 pathway as a novel approach to enhance host immunity and develop innovative control measures against malaria.

4.2 *Leishmania* Manipulates the TLR3 Signaling Pathway to Promote Infection

Leishmaniasis is caused by *Leishmania* spp., which is transmitted to humans, mammals (such as dogs and rats), and certain reptiles (such as lizards) through the bite of a sandfly [92]. Leishmaniasis is a zoonotic parasitic disease endemic to numerous regions, including parts of North America such as the United States and Canada, posing a significant risk to human health [93]. Leishmaniasis exhibits a range of clinical manifestations, from skin lesions to potentially fatal visceral involvement [92,94].

The immune responses elicited during *Leishmania* infection are pivotal in determining disease outcomes, particularly through mechanisms such as TLR3 signaling, which shapes cytokine profiles and regulates immune cell activity [45,95]. TLR3 initiates a cascade of host immune responses by recognizing exoRNA released from damaged cells following *Leishmania* infection [22,96]. Infection with *Leishmania amazonensis* (*L. amazonensis*) disrupts the host immune response and suppresses macrophage function [97, 98]. This disruption includes alterations in cytokine production, such as restricted IFN- γ expression, accompanied by increased levels of IL-10 and TGF- β and decreased levels of IFN- β [99,100]. This altered cytokine profile




Fig. 3. TLR3-mediated immune responses in parasite infections. (a) ExoRNA released by *Plasmodium*-infected red blood cells activates TLR3, thereby promoting the transcription of cytokines such as IFN- γ and IL-12. IL-12 stimulates NKT cells to produce IFN- γ , while IFN- γ enhances the activity of CD19⁺ TLR3⁺ B cells through NK cells. This interaction suppresses IgG production within the host, aggravating *Plasmodium* infection and contributing to the delayed clearance of the parasite. (b) ExoRNA released by *Leishmania*-infected macrophages activates TLR3, promoting the transcription of IL-6, IFN- β , and IL-10, while suppressing the transcription of IL-12. IL-6 activates Th₁₇ cells, and in synergy with other cytokines, exacerbates the progression of leishmaniasis. (c) TLR3 can be activated by exoRNA derived from *C. sinensis* residing in the host liver and bile ducts, as well as by the TLR3 agonist poly(I:C). This activation promotes the transcription of IFN- γ while inhibiting the transcription of TNF- α and IL-6, effectively alleviating liver damage caused by the parasitic infection. (d) TLR3 can be activated by exoRNA derived from *S. japonicum* residing in the host venous system, as well as by the TLR3 agonist poly(I:C). This activation promotes the transcription of cytokines such as IFN- γ , IL-4, IL-5, and IL-17, leading to NK cell expression through Th₂ cells and exacerbating liver damage caused by the parasitic infection. (e) TLR3 cannot be activated by exoRNA derived from *T. spiralis* residing in host muscle cells but can be activated by the TLR3 agonist poly(I:C). This activation promotes the transcription of IFN- γ , IL-2, and IL-6 while inhibiting the transcription of IL-4 and IL-10, thereby regulating *T. spiralis* infection to effectively reduce the parasite burden. (f) TLR3 can be activated by lncRNA derived from macrophages infected with *N. caninum*. This activation promotes the transcription of cytokines IFN- γ and IL-12p40, enhancing the specific Th₁ response, which enables the host to better control *N. caninum* infection. Created with [BioRender.com](https://www.biorender.com).

contributes to the development of cutaneous leishmaniasis [101]. Moreover, as illustrated in Fig. 3b, activation of the TLR3-TRIF pathway during *L. amazonensis* infection enhances the production of IL-6, as well as that of other cytokines and chemokines, which promotes the polarization

of T cells toward a Th₁₇ phenotype. This response facilitates parasite spread and aggravates disease severity [102]. The upregulation of macrophages induced by TLR3 activation also leads to elevated IFN- β and IL-10 levels, while concurrently suppressing IL-12 expression, thus exacerbat-

Table 1. Research progress of TLR3 during different parasite infections.

Parasite	Detailed information	Reference
<i>Plasmodium yoelii yoelii</i> 265 BY (<i>P. yoelii yoelii</i> 265 BY)	Host: 6–8 weeks old C57BL/6J mice and TLR3-knockout mice Study Organ: Liver and Spleen Cellular and Cytokine changes: CD19 ⁺ TLR3 ⁺ ↑, IFN- γ ↑, TNF- α ↑, and IgG↓ Result: Compared to WT mice, TLR3-knockout mice exhibited a significant increase in parasite-specific antibodies when infected with <i>P. yoelii yoelii</i> 265 BY. These mice demonstrated better control over the growth of <i>Plasmodium</i> and cleared the parasite earlier during infection. In WT mice infected with <i>P. yoelii yoelii</i> 265 BY, there was an elevated frequency of CD19 ⁺ and TLR3 ⁺ B cells, a decrease in overall IgG levels, and an increase in TNF- α and IFN- γ levels in the liver at 42 h. These changes also influenced the quantity and quality of the antibody response.	[46]
<i>Leishmania amazonensis</i> (<i>L. amazonensis</i>)	Host: 6–8 weeks old C57BL/6 mice and TLR3-knockout mice Study Organ: Skin Cellular and Cytokine changes: IFN- β ↑, IL-10↑, and IL-12↓ Result: This study concluded that <i>L. amazonensis</i> enhanced its survival within host macrophages by activating the TLR3 signalling pathway, promoting the expression of IFN- β and IL-10, while suppressing the production of IL-12, which helped to inhibit the host's immune response, thereby allowing the parasite to continue to proliferate.	[43]
<i>Clonorchis sinensis</i> (<i>C. sinensis</i>)	Host: 6–8 weeks old C57BL/6 mice and TLR3-knockout mice Study Organ: Liver and Bile Ducts Cellular and Cytokine changes: IFN- γ ↑, IL-4↓, IL-6↓, and TNF- α ↓ Result: TLR3-knockout mice exhibited significantly lower body weights, higher mortality rates, and increased parasite loads compared to WT mice. The absence of TLR3 further exacerbated liver injury and inflammatory responses, leading to increased hepatic fibrosis in infected mice.	[47]
<i>Schistosoma japonicum</i> (<i>S. japonicum</i>)	Host: C57BL/6 mice Study Organ: Liver and Spleen Cellular and Cytokine changes: IL-4↑, IL-5↑, IL-17↑, and IFN- γ ↑ Result: The percentage of cells producing IFN- γ , IL-4, IL-5 and IL-17 in the TLR3 ⁺ NK cell population of infected mice was significantly increased, but the result was just the opposite in TLR3-knockout mice. TLR3 deficiency can significantly reduce the levels of aspartate aminotransferase and alanine aminotransferase, which are important indicators of liver fibrosis, reduce the number of white blood cells in peripheral blood, and restore the number of red blood cells, platelets and hemoglobin content in peripheral blood of infected mice, thus inhibiting the development of schistosomiasis. This indicates that the deletion of TLR3 reduces liver damage during infection, and there is a positive correlation between TLR3 and the severity of liver pathogenesis, that is, TLR3 is involved in the granulomatous inflammatory response during <i>S. japonicum</i> infection.	[8,90]
<i>Trichinella spiralis</i> (<i>T. spiralis</i>)	Host: 6–8 weeks old female C57BL/6 mice with poly(I:C) treatment Study Organ: Spleen Cellular and Cytokine changes: IFN- γ ↑, IL-2↑, IL-6↑, IL-4↓, and IL-10↓ Result: Compared to WT mice, treatment with poly(I:C) led to a significant increase in Th ₁ -type cytokines, including IFN- γ and IL-2, as well as Th ₂ -type cytokine IL-6. Conversely, there was a notable decrease in anti-inflammatory cytokines such as Th ₂ cytokines IL-4 and IL-10. These changes resulted in a significant reduction in the parasite load and ultimately hindered the proliferation of <i>Trichinella spiralis</i> .	[52]
<i>Neospora caninum</i> (<i>N. caninum</i>)	Host: 6–8 weeks old C57BL/6 mice, TRIF-knockout mice and TLR3-knockout mice Study Organ: Spleen, Lung and Brain Cellular and Cytokine changes: IL-12p40↑, IFN- γ ↑, and Th ₁ ↑ Result: When WT mice TLR3 recognize <i>N. caninum</i> , inducible IL-12p40 secretion promotes IFN- γ production to inhibit the <i>N. caninum</i> infection. The TLR3-TRIF pathway enhances the Th ₁ immune response against the parasite, thereby improving host survival, reducing parasite load, and decreasing the inflammatory lesions of the host. This immune response effectively resists <i>N. caninum</i> infection.	[44,91]

Note: activation, stimulation of secretion or increased expression ↑; inhibition of secretion or decreased expression ↓.

ing the pathogenicity of *L. amazonensis*. As presented in Table 1, TLR3 activation enhances the expression of both IFN- β and IL-10. Thus, TLR3 appears essential for the intracellular survival and proliferation of *L. amazonensis* [43]. Furthermore, the *Leishmania* RNA virus also activates the TLR3-TRIF signaling pathway, promoting the production of IFN- α/β . As a result, the expression of autophagy-related 5 is induced, which mediates the degradation of nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) and apoptosis-associated speck-like protein containing a caspase activation and recruitment domain, thereby inhibiting inflammasome activation [103,104]. This suggests that *Leishmania* parasites, through their interactions with TLR3 and other immune pathways, modulate the host immune response to enhance their survival and pathogenicity.

In conclusion, the complex immune modulation observed during *Leishmania* infection, particularly via TLR3-mediated pathways, underscores the parasite's capacity to manipulate host immune responses to support its intracellular survival and propagate disease. Further research focusing on these immune pathways could provide crucial insights into developing novel therapeutic strategies to control leishmaniasis progression and severity.

4.3 Inhibition of Inflammatory Signaling by TLR3 Regulates Hepatic Fibrosis During *C. sinensis* Infection

Clonorchiasis is caused by *Clonorchis sinensis* (*C. sinensis*), a liver fluke from the family Opisthorchiidae, infecting humans or mammals through the consumption of undercooked freshwater fish containing encysted metacercariae [105]. This disease is prevalent mainly in parts of China and other East Asian countries [106]. Over 15 million people are, reportedly, infected with the parasite, with more than 80% of the infections occurring in China. Consequently, it is considered one of the most widespread and detrimental food-borne parasitic diseases in China [7,107]. Infection with *C. sinensis* leads to various pathological changes such as epithelial cell proliferation, degeneration, liver inflammation, cholangitis, and bile duct obstruction. If left untreated, this long-term infection can result in bile duct fibrosis, liver cirrhosis, and even cholangiocarcinoma [108].

A recent study has highlighted the significant role of TLR3 activation in liver fibrosis associated with *C. sinensis*, emphasizing its importance as a target in modulating hepatic stellate cell activation and promoting liver regeneration [47]. Activation of TLR3 using poly(I:C) promotes the regeneration of damaged liver tissue due to *C. sinensis* infection [109]. TLR3 may potentially detect exocytotic RNA released from host cells damaged by *C. sinensis* infection [22,110]. Compared to WT mice, TLR3-knockout mice exhibit hyperactivation of pro-inflammatory pathways such as ERK, p38, AKT, and p65, along with increased expression of cytokines IL-4, IL-6, and TNF- α , and reduced expres-

sion of IFN- γ . This imbalance leads to exacerbated hepatic inflammation and fibrosis. The immune response triggered by TLR3 signaling during *C. sinensis* infection is pivotal in regulating liver pathology, impacting both the development and resolution of hepatic fibrosis. In contrast, as depicted in Fig. 3c, WT mice infected with *C. sinensis* activate the TLR3 signaling pathway, which inhibits the release of IL-6 and TNF- α , while upregulating IFN- γ expression [47]. Notably, TLR3-regulated cytokines such as TNF- α and IL-4 are significantly elevated and positively correlated with fibrosis severity [111–113]. Whereas IFN- γ promotes the gradual regression of hepatic fibrosis by inducing hepatic stellate cell apoptosis [114]. This finding underscores the crucial role of IFN- γ within the TLR3 pathway in mitigating liver fibrosis. Therefore, the role of poly(I:C) in liver disease appears to be dualistic. Specifically, treatment with poly(I:C) in C57BL/6 mice non-pathogenic liver disease is associated with the induction of primary biliary cirrhosis [115]. However, as indicated in Table 1, poly(I:C)-treated mice infected with *C. sinensis* exhibit a significantly lower degree of hepatic fibrosis than that of untreated controls, indicating effective alleviation of liver damage. These observations suggest a protective role of TLR3 in controlling liver fibrosis induced by *C. sinensis* [47].

In conclusion, TLR3 signaling plays a pivotal role in modulating the immune response and hepatic fibrosis during *C. sinensis* infection, with its activation demonstrating protective effects against liver damage. Future studies should aim to elucidate the dual role of TLR3 in liver diseases to better leverage its therapeutic potential for managing fibrosis and other liver pathologies.

4.4 The Role of TLR3 in Modulating Immune Responses and Liver Pathogenesis During *Schistosoma japonicum* Infection

Schistosoma japonicum is a dioecious zoonotic parasite in the family Schistosomatidae, causing schistosomiasis in 78 tropical and subtropical countries, particularly where medical resources are limited, and thus posing a major threat to human health and economic development [116–118]. The cercariae of *S. japonicum* are released into freshwater environments by their intermediate host, the *Oncomelania* snail, contaminating water sources. The end hosts are vertebrates, including humans, who become infected with schistosomiasis through exposure to this contaminated water [119]. The damage caused by *S. japonicum* to the host, particularly from parasitized eggs, can be severe and varies in magnitude [120,121]. Schistosomiasis represents a significant public health challenge, causing chronic inflammation and organ damage that leads to genitourinary and intestinal complications. This, in turn, severely impairs the quality of life, especially in affected populations [122].

Upon *S. japonicum* infection, the host initiates a variety of immune responses, with NK cells playing a crucial role. These cells, integral to the innate immune system, re-

spond rapidly to pathogens through cytotoxic mechanisms and cytokine secretion [123]. Recent studies suggest that TLR3 detects exoRNA released from damaged host cells during *S. japonicum* infection [53,124]. In experimental models, *S. japonicum*-infected mice showed increased secretion of IFN- γ and IL-4, as illustrated in Fig. 3d [122]. *In vitro* experiments confirmed these findings, revealing that murine spleen cells pre-stimulated with poly(I:C) and co-cultured with *S. japonicum* produced significantly higher IL-4 levels. Additionally, *S. japonicum*-infected mice exhibited a higher proportion of TLR3⁺ NK cells in the spleen compared to uninfected controls, along with increased expression of IL-4, IL-5, and IL-17. In contrast, TLR3-deficient mice showed a marked reduction in these cytokines, underscoring TLR3's role in activating splenic NK cells during infection [90]. Moreover, TLR3-mediated immune responses were found to vary across tissues due to organ-specific factors [8,90]. Notably, TLR3 deficiency in infected mice led to reduced levels of aspartate aminotransferase and alanine aminotransferase, lower peripheral leukocyte counts, and normalized erythrocyte, platelet, and hemoglobin levels, as summarized in Table 1. These results suggest that TLR3 is positively associated with liver pathology severity, and its absence helps alleviate liver injury during infection [8].

4.5 TLR3 Agonist Poly(I:C) Immunomodulates *Trichinella spiralis* Infection

Trichinellosis is caused by *Trichinella spiralis* (*T. spiralis*), which belongs to the nematode order of the phylum Aschelminthes [125]. The life cycle of this species consists of three distinct phases: the myxo-larval, adult, and neonatal larval stages, all of which occur within a common host organism [126]. Poor dietary habits, such as consumption of raw or undercooked pork or wild game contaminated with trichinella larvae, can lead to *T. spiralis* infections in a wide range of mammals, including humans and pigs [127]. During the acute phase of infection, individuals commonly exhibit symptoms such as increased body temperature; these symptoms can persist for multiple weeks and potentially result in organ dysfunction [128]. In certain cases, the mortality rate of *T. spiralis* infection may soar up to 30% [129]. As of 2023, the health of people living in the African continent continues to be threatened by *T. spiralis* [130].

Building on the understanding of immune regulation induced by *T. spiralis*, current research is delving into the underlying molecular mechanisms through which the parasite evades the immune system, aiming to identify novel molecular targets for therapeutic intervention against *T. spiralis*. This pathogen modulates the host immune response by regulating the expression of TLRs, thereby influencing cytokine expression at various stages of infection [131]. TLR agonists have a wide range of therapeutic applications, including their use in signal therapy to accelerate and en-

hance vaccine-specific immune responses [132]. TLR3, as a commonly used vaccine adjuvant, plays an important role in host resistance to pathogen infection [133]. Although *T. spiralis* infection induces the release of exoRNA from damaged host cells, this exoRNA either fails to be recognized by TLR3 or the parasite successfully evades the host immune response [22,53,134]. Notably, the administration of poly(I:C) results in consistently elevated TLR3 expression and significantly increased levels of serum IFN- γ , IL-2, and IL-6 in C57BL/6 female mice compared to the control group, accompanied by significantly reduced IL-10 and IL-4 levels (Fig. 3e and Table 1). These findings suggest that TLR3-targeted therapy may be effective in reducing worm burden by modulating cytokine levels in *T. spiralis*-infected mice. Notably, poly(I:C) proved more effective at blocking the immune evasion strategy of *T. spiralis* compared to agonists targeting TLR4, TLR8, and TLR9 [52]. As *T. spiralis* is suggested to successfully escape the host TLR3-mediated immune response under natural circumstances, poly(I:C) represents a promising therapeutic approach with great potential in controlling *T. spiralis* infections.

4.6 The Role of TLR3-TRIF Pathway in Modulating Immune Responses Against *Neospora caninum* Infection

Neosporosis is caused by the protozoan parasite *N. caninum*, belonging to the phylum Apicomplexa. It primarily infects intermediate hosts like pigs, sheep, horses, cattle, and rabbits via oral or transplacental transmission, in addition to parasitizing definitive hosts such as dogs and other canids [135]. It is globally distributed and represents a major etiological agent of abortion in pregnant cattle, leading to considerable economic losses in the livestock industry [136]. Although *N. caninum* has not yet been classified as a zoonotic pathogen, environmental studies have highlighted its potential to pose a significant risk to human health, warranting further investigation [137,138].

The recognition of *N. caninum* by host immune receptors, particularly TLR3, highlights the critical interplay between innate immune sensing and the subsequent adaptive immune responses, which are essential for controlling infection and mitigating pathogenic effects. TLR3 may recognize lncRNAs produced by host cells in response to *N. caninum* infection [139,140]. This recognition triggers the production of various cytokines and chemokines, including IL-12 and IFN- γ , which further promote immune cell activation and inflammatory responses. Compared to WT mice, TLR3-knockout mice exhibit reduced IL-12p40 secretion, increased parasite burden, and decreased survival rates following *N. caninum* infection [44]. Upon recognition of *N. caninum* by TLR3, the inducible secretion of IL-12p40 promotes IFN- γ production, thereby inhibiting infection in mice. Further research involving experiments in WT mice, TLR3-knockout mice, and TLR3-knockout mice supplemented with IL-12p40 demonstrated that IL-12p40 exerts paracrine effects on infected activated macrophages

to control parasite proliferation. Moreover, the TLR3-TRIF signaling pathway induces ERK phosphorylation, facilitating the recognition of *N. caninum* and triggering IL-12p40 production. This mechanism plays a crucial role in controlling *N. caninum* proliferation in C57BL/6 mice [51]. These findings suggest that the TLR3 pathway promotes the production of IL-12p40 and IFN- γ and enhances specific Th₁ responses (Fig. 3f and Table 1), potentially enabling the host to better regulate the effects of *N. caninum* infection [44,91]. Therefore, understanding the detailed mechanisms through which the TLR3-TRIF pathway initiates Th₁ responses could provide novel insights for developing targeted therapeutic strategies aimed at mitigating the impact of *N. caninum* infection in livestock, with potential implications for safeguarding public health.

5. Conclusions

TLR3 plays a complex role in parasitic infections, contributing to both protective immunity and immune-mediated pathologies through a delicate balance. It recognizes parasite-derived nucleic acids, such as exoRNA and lncRNA, and regulates immune cells like macrophages and NK cells to enhance host defenses. However, its activation can also lead to excessive inflammation, resulting in tissue damage, fibrosis, and exacerbating parasitic diseases. The interplay between TLR3 and other TLRs amplifies immune responses, highlighting its critical role in both innate and adaptive immunity.

In various parasitic infections, TLR3's effects are host-dependent. For example, during *Plasmodium* infection, TLR3 triggers the production of pro-inflammatory cytokines essential for parasite clearance, but excessive activation can cause tissue damage. In *C. sinensis* infections, TLR3 activation is protective, reducing liver fibrosis and injury by modulating inflammatory and anti-inflammatory cytokines. In contrast, in *S. japonicum* infections, TLR3 exacerbates granulomatous inflammation and liver pathology, with its deficiency mitigating these effects. Similarly, in *L. amazonensis* infections, TLR3 skews the immune response towards a Th₁₇ phenotype, promoting parasite survival and disease progression. In *T. spiralis* infections, TLR3 activation enhances Th₁ responses, helping to limit parasite burdens. In *N. caninum* infections, TLR3-mediated production of IL-12p40 and IFN- γ drives robust Th₁ immunity, enhancing parasite clearance and reducing inflammation.

These findings highlight TLR3's multifaceted roles in parasitic infections, acting both as a defender against pathogens and a contributor to immune-mediated damage. Understanding its dual functions is key to unraveling host-parasite interactions and positions TLR3 as a promising therapeutic target. Targeting TLR3 in parasitic infections holds potential for improving immune defense while minimizing harmful inflammation. Future research should focus on deciphering the precise mechanisms through which TLR3 mediates its diverse roles in different parasitic dis-

eases. Developing specific TLR3 agonists or antagonists tailored to the infection type may offer innovative approaches to disease management. Additionally, understanding the cross-regulation between TLR3 and other immune pathways could pave the way for strategies to fine-tune immune responses. Insights from these studies may contribute to advancing vaccines, immunotherapies, and targeted treatments, ultimately improving patient outcomes and reducing the global burden of parasitic diseases.

Abbreviations

C. sinensis, *Clonorchis sinensis*; DCs, dendritic cells; dsRNA, double-stranded RNA; exoRNA, exosomal RNA; IFN- α/β , type I interferons; IKK, inhibitor of kappa B kinase; IL, interleukin; IRF, interferon regulatory factors; ISGs, interferon-stimulated genes; *L. amazonensis*, *Leishmania amazonensis*; lncRNA, long non-coding RNA; MAPKs, mitogen-activated protein kinases; *N. caninum*, *Neospora caninum*; NEMO, NF- κ B essential modulator; NF- κ B, nuclear factor κ B; NK, natural killer; *P. yoelii yoelii* 265 BY, *Plasmodium yoelii yoelii* 265 BY; *S. japonicum*, *Schistosoma japonicum*; TAB2, TAK1-binding protein 2; TAK1, TGF- β -activated kinase 1; TBK1, TANK-binding kinase 1; TGF- β , transforming growth factor- β ; TNF- α , tumor necrosis factor-alpha; TLR, Toll-like receptor; TRAF6, tumor necrosis factor receptor-associated factor 6; TRIF, TIR-domain-containing adapter-inducing interferon- β ; *T. spiralis*, *Trichinella spiralis*.

Author Contributions

YY, QL, YZ, NJ, and QC designed and wrote the manuscript. YY, QL, YZ, NJ, and QC were involved in original draft preparation; YY, QL, YZ, NJ, and QC participated in reviewing and editing. YZ and NJ contributed to the design of the figures. QC finalized the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

Not applicable.

Acknowledgment

We thank the researchers for their wonderful work on TLR3 and apologize to those who are not cited in this manuscript owing to the limited space.

Funding

This research was supported by a grant from the National Key Research and Development Program of China (grant number 2022YFD1800200), the National Nature and Science Foundation of China (grant number 82030060), and the CAMS Innovation Fund for Medical Sciences (CIFMS) (grant number 2019-I2M-5-042).

Conflict of Interest

The authors declare no conflict of interest.

References

- [1] Chen J, Liu Q, Liu GH, Zheng WB, Hong SJ, Sugiyama H, *et al.* Toxocariasis: a silent threat with a progressive public health impact. *Infectious Diseases of Poverty*. 2018; 7: 59. <https://doi.org/10.1186/s40249-018-0437-0>.
- [2] Ponce-Gordo F, García-Rodríguez JJ. *Balantioides coli*. Research in Veterinary Science. 2021; 135: 424–431. <https://doi.org/10.1016/j.rvsc.2020.10.028>.
- [3] Prüss-Ustün A, Wolf J, Bartram J, Clasen T, Cumming O, Freeman MC, *et al.* Burden of disease from inadequate water, sanitation and hygiene for selected adverse health outcomes: An updated analysis with a focus on low- and middle-income countries. *International Journal of Hygiene and Environmental Health*. 2019; 222: 765–777. <https://doi.org/10.1016/j.ijheh.2019.05.004>.
- [4] Tsukanov VV, Vasyutin AV, Tonkikh JL. Parasites of the liver: A global problem? *World Journal of Gastroenterology*. 2024; 30: 3554–3559. <https://doi.org/10.3748/wjg.v30.i30.3554>.
- [5] Su XZ, Lane KD, Xia L, Sá JM, Wellems TE. *Plasmodium* Genomics and Genetics: New Insights into Malaria Pathogenesis, Drug Resistance, Epidemiology, and Evolution. *Clinical Microbiology Reviews*. 2019; 32: e00019–19. <https://doi.org/10.1128/CMR.00019-19>.
- [6] Baneth G, Solano-Gallego L. Leishmaniasis. *The Veterinary Clinics of North America. Small Animal Practice*. 2022; 52: 1359–1375. <https://doi.org/10.1016/j.cvsm.2022.06.012>.
- [7] Qian MB, Jiang ZH, Ge T, Wang X, Zhou CH, Zhu HH, *et al.* Rapid screening of *Clonorchis sinensis* infection: Performance of a method based on raw-freshwater fish-eating practice. *Acta Tropica*. 2020; 207: 105380. <https://doi.org/10.1016/j.actatropica.2020.105380>.
- [8] Xie H, Chen D, Feng Y, Mo F, Liu L, Xing J, *et al.* Evaluation of the TLR3 involvement during *Schistosoma japonicum*-induced pathology. *BMC Immunology*. 2024; 25: 2. <https://doi.org/10.1186/s12865-023-00586-9>.
- [9] Ashour DS, Ibrahim FMK, Elshamy AM, Zoghroban HS. *Trichinella spiralis*-derived extracellular vesicles induce a protective immunity against larval challenge in mice. *Pathogens and Disease*. 2022; 80: ftac040. <https://doi.org/10.1093/femspd/ftac040>.
- [10] Del'Arco AE, Argolo DS, Guillemin G, Costa MDFD, Costa SL, Pinheiro AM. Neurological Infection, Kynurenine Pathway, and Parasitic Infection by *Neospora caninum*. *Frontiers in Immunology*. 2022; 12: 714248. <https://doi.org/10.3389/fimmu.2021.714248>.
- [11] Belachew EB. Immune Response and Evasion Mechanisms of *Plasmodium falciparum* Parasites. *Journal of Immunology Research*. 2018; 2018: 6529681. <https://doi.org/10.1155/2018/6529681>.
- [12] Bekkering S, Domínguez-Andrés J, Joosten LAB, Riksen NP, Netea MG. Trained Immunity: Reprogramming Innate Immunity in Health and Disease. *Annual Review of Immunology*. 2021; 39: 667–693. <https://doi.org/10.1146/annurev-immunol-102119-073855>.
- [13] Nandan D, Brar HK, Reiner N. Manipulation of Macrophages: Emerging Mechanisms of Leishmaniasis. *Frontiers in Bioscience (Landmark Edition)*. 2024; 29: 292. <https://doi.org/10.31083/j.fbl2908292>.
- [14] Carty M, Guy C, Bowie AG. Detection of Viral Infections by Innate Immunity. *Biochemical Pharmacology*. 2021; 183: 114316. <https://doi.org/10.1016/j.bcp.2020.114316>.
- [15] Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. *Cell*. 2020; 180: 1044–1066. <https://doi.org/10.1016/j.cell.2020.02.041>.
- [16] Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell*. 2010; 140: 805–820. <https://doi.org/10.1016/j.cell.2010.01.022>.
- [17] Yang Q, Shu HB. Deciphering the pathways to antiviral innate immunity and inflammation. *Advances in Immunology*. 2020; 145: 1–36. <https://doi.org/10.1016/bs.ai.2019.11.001>.
- [18] Uyangaa E, Choi JY, Park SO, Byeon HW, Cho HW, Kim K, *et al.* TLR3/TRIF pathway confers protection against herpes simplex encephalitis through NK cell activation mediated by a loop of type I IFN and IL-15 from epithelial and dendritic cells. *Immunology*. 2023; 170: 83–104. <https://doi.org/10.1111/imm.13664>.
- [19] Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. *Oncoimmunology*. 2020; 9: 1771143. <https://doi.org/10.1080/2162402X.2020.1771143>.
- [20] Chen CY, Shih YC, Hung YF, Hsueh YP. Beyond defense: regulation of neuronal morphogenesis and brain functions via Toll-like receptors. *Journal of Biomedical Science*. 2019; 26: 90. <https://doi.org/10.1186/s12929-019-0584-z>.
- [21] Alvarado-Morales I, Olivares-Illana V, Arenas-Huerta C, Reynaga-Hernández E, Layseca-Espinosa E, Tokar EJ, *et al.* Human prostate epithelial cells and prostate-derived stem cells malignantly transformed in vitro with sodium arsenite show impaired Toll like receptor -3 (TLR3)-associated anti-tumor pathway. *Toxicology Letters*. 2021; 350: 185–193. <https://doi.org/10.1016/j.toxlet.2021.07.013>.
- [22] Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X, *et al.* Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. *Cancer Cell*. 2016; 30: 243–256. <https://doi.org/10.1016/j.ccell.2016.06.021>.
- [23] Gao D, Ciancanelli MJ, Zhang P, Harschnitz O, Bondet V, Hasek M, *et al.* TLR3 controls constitutive IFN- β antiviral immunity in human fibroblasts and cortical neurons. *The Journal of Clinical Investigation*. 2021; 131: e134529. <https://doi.org/10.1172/JCI134529>.
- [24] Bugge M, Bergstrom B, Eide OK, Solli H, Kjønstad IF, Stenvik J, *et al.* Surface Toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness. *The Journal of Biological Chemistry*. 2017; 292: 15408–15425. <https://doi.org/10.1074/jbc.M117.784090>.
- [25] Matsumoto M, Oshiumi H, Seya T. Antiviral responses induced by the TLR3 pathway. *Reviews in Medical Virology*. 2011; 21: 67–77. <https://doi.org/10.1002/rmv.680>.
- [26] Maney SK, Xu HC, Huang J, Pandya AA, Ehlting C, Aguilar-Valenzuela R, *et al.* RAIDD Mediates TLR3 and IRF7 Driven Type I Interferon Production. *Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*. 2016; 39: 1271–1280. <https://doi.org/10.1159/000447832>.
- [27] Zhou R, Zhang Q, Xu P. TBK1, a central kinase in innate immune sensing of nucleic acids and beyond. *Acta Biochimica et Biophysica Sinica*. 2020; 52: 757–767. <https://doi.org/10.1093/abbs/gmaa051>.
- [28] Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. *Immunity*. 2006; 25: 349–360. <https://doi.org/10.1016/j.immuni.2006.08.009>.
- [29] Chen Y, Lin J, Zhao Y, Ma X, Yi H. Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses. *Journal of Zhejiang University. Science. B*. 2021; 22: 609–632. <https://doi.org/10.1631/jzus.B2000808>.

- [30] Emmerich CH, Ordureau A, Strickson S, Arthur JSC, Pedrioli PGA, Komander D, *et al.* Activation of the canonical IKK complex by K63/M1-linked hybrid ubiquitin chains. *Proceedings of the National Academy of Sciences of the United States of America*. 2013; 110: 15247–15252. <https://doi.org/10.1073/pnas.1314715110>.
- [31] Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. *Wiley Interdisciplinary Reviews. Systems Biology and Medicine*. 2016; 8: 227–241. <https://doi.org/10.1002/wsbm.1331>.
- [32] Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. *Medical Microbiology and Immunology*. 2015; 204: 11–20. <https://doi.org/10.1007/s00430-014-0370-1>.
- [33] Zhang Y, Chen S, Jin Y, Ji W, Zhang W, Duan G. An Update on Innate Immune Responses during SARS-CoV-2 Infection. *Viruses*. 2021; 13: 2060. <https://doi.org/10.3390/v13102060>.
- [34] Ha YE, Ju So Y, Im J, Yun CH, Park JC, Hyun Han S. TLR3 recognition of viral double-stranded RNA in human dental pulp cells is important for the innate immunity. *International Immunopharmacology*. 2023; 119: 110161. <https://doi.org/10.1016/j.intimp.2023.110161>.
- [35] Madera S, Rapp M, Firth MA, Beilke JN, Lanier LL, Sun JC. Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide. *The Journal of Experimental Medicine*. 2016; 213: 225–233. <https://doi.org/10.1084/jem.20150712>.
- [36] Beiting DP, Peixoto L, Akopyants NS, Beverley SM, Wherry EJ, Christian DA, *et al.* Differential induction of TLR3-dependent innate immune signaling by closely related parasite species. *PLoS One*. 2014; 9: e88398. <https://doi.org/10.1371/journal.pone.0088398>.
- [37] Chen JG, Liu SC, Nie Q, Du YT, Lv YY, He LP, *et al.* Exosome-derived long noncoding RNAs: Mediators of host-Plasmodium parasite communication. *Wiley Interdisciplinary Reviews. RNA*. 2023; e1808. <https://doi.org/10.1002/wrna.1808>.
- [38] de Souza W, Barrias ES. Membrane-bound extracellular vesicles secreted by parasitic protozoa: cellular structures involved in the communication between cells. *Parasitology Research*. 2020; 119: 2005–2023. <https://doi.org/10.1007/s00436-020-06691-7>.
- [39] Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. *Nature Reviews. Immunology*. 2014; 14: 36–49. <https://doi.org/10.1038/nri3581>.
- [40] Lang KS, Georgiev P, Recher M, Navarini AA, Bergthaler A, Heikenwalder M, *et al.* Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. *The Journal of Clinical Investigation*. 2006; 116: 2456–2463. <https://doi.org/10.1172/JCI28349>.
- [41] Chandrasekaran S, Kochanowsky JA, Merritt EF, Lagas JS, Swannigan A, Koshy AA. IFN-γ stimulated murine and human neurons mount anti-parasitic defenses against the intracellular parasite *Toxoplasma gondii*. *Nature Communications*. 2022; 13: 4605. <https://doi.org/10.1038/s41467-022-32225-z>.
- [42] Jafarzadeh A, Nemati M, Salarkia E, Yadav S, Aminizadeh N, Jafarzadeh S, *et al.* Inflammatory responses during trichomoniasis: The role of Toll-like receptors and inflammasomes. *Parasite Immunology*. 2023; 45: e13000. <https://doi.org/10.1111/pim.13000>.
- [43] Rath CT, Vivarini AC, Dos Santos JV, Medina JM, Saliba AM, Mottram JC, *et al.* Toll-Like Receptor 3 (TLR3) Is Engaged in the Intracellular Survival of the Protozoan Parasite *Leishmania (Leishmania) amazonensis*. *Infection and Immunity*. 2022; 90: e0032422. <https://doi.org/10.1128/iai.00324-22>.
- [44] Miranda VDS, França FBF, da Costa MS, Silva VRS, Mota CM, Barros PDSC, *et al.* Toll-Like Receptor 3-TRIF Pathway Activation by *Neospora caninum* RNA Enhances Infection Control in Mice. *Infection and Immunity*. 2019; 87: e00739–18. <https://doi.org/10.1128/IAI.00739-18>.
- [45] de Carvalho RVH, Lima-Junior DS, da Silva MVG, Dilucca M, Rodrigues TS, Horta CV, *et al.* Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibition. *Nature Communications*. 2019; 10: 5273. <https://doi.org/10.1038/s41467-019-13356-2>.
- [46] Keswani T, Delcroix-Genete D, Herbert F, Leleu I, Lambert C, Draheim M, *et al.* *Plasmodium yoelii* Uses a TLR3-Dependent Pathway to Achieve Mammalian Host Parasitism. *Journal of Immunology (Baltimore, Md.: 1950)*. 2020; 205: 3071–3082. <https://doi.org/10.4049/jimmunol.1901317>.
- [47] Wang Y, Gong P, Zhang X, Wang X, Zhang X, Zhang N, *et al.* TLR3 activation by *Clonorchis sinensis* infection alleviates the fluke-induced liver fibrosis. *PLoS Neglected Tropical Diseases*. 2023; 17: e0011325. <https://doi.org/10.1371/journal.pntd.0011325>.
- [48] Zhang Q, Bastard P, COVID Human Genetic Effort, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. *Nature*. 2022; 603: 587–598. <https://doi.org/10.1038/s41586-022-04447-0>.
- [49] Croci S, Venneri MA, Mantovani S, Fallerini C, Benetti E, Picchiotti N, *et al.* The polymorphism L412F in *TLR3* inhibits autophagy and is a marker of severe COVID-19 in males. *Autophagy*. 2022; 18: 1662–1672. <https://doi.org/10.1080/15548627.2021.1995152>.
- [50] Arefinia N, Banafi P, Zarezadeh MA, Mousawi HS, Yaghobi R, Farokhnia M, *et al.* TLR3, TLR7, and TLR8 genes expression datasets in COVID-19 patients: Influences of the disease severity and gender. *Data in Brief*. 2024; 54: 110498. <https://doi.org/10.1016/j.dib.2024.110498>.
- [51] Zhang X, Li X, Gong P, Wang X, Zhang N, Chen M, *et al.* Host defense against *Neospora caninum* infection via IL-12p40 production through TLR2/TLR3-AKT-ERK signaling pathway in C57BL/6 mice. *Molecular Immunology*. 2021; 139: 140–152. <https://doi.org/10.1016/j.molimm.2021.08.019>.
- [52] Tang B, Liu X, Liu M, Bai X, Wang Y, Ding J, *et al.* Effects of TLR agonists on immune responses in *Trichinella spiralis* infected mice. *Parasitology Research*. 2020; 119: 2505–2510. <https://doi.org/10.1007/s00436-020-06747-8>.
- [53] Zhang X, Gao R, Zhang C, Teng Y, Chen H, Li Q, *et al.* Extracellular RNAs-TLR3 signaling contributes to cognitive impairment after chronic neuropathic pain in mice. *Signal Transduction and Targeted Therapy*. 2023; 8: 292. <https://doi.org/10.1038/s41392-023-01543-z>.
- [54] de Bruin AM, Voermans C, Nolte MA. Impact of interferon-γ on hematopoiesis. *Blood*. 2014; 124: 2479–2486. <https://doi.org/10.1182/blood-2014-04-568451>.
- [55] Hojo-Souza NS, de Azevedo PO, de Castro JT, Teixeira-Carvalho A, Lieberman J, Junqueira C, *et al.* Contributions of IFN-γ and granulysin to the clearance of *Plasmodium yoelii* blood stage. *PLoS Pathogens*. 2020; 16: e1008840. <https://doi.org/10.1371/journal.ppat.1008840>.
- [56] Sanchez MV, Eliçabe RJ, Di Genaro MS, Germanó MJ, Gea S, García Bustos MF, *et al.* Total *Leishmania* antigens with Poly(I:C) induce Th1 protective response. *Parasite Immunology*. 2017; 39. <https://doi.org/10.1111/pim.12491>.
- [57] Mehrizi AA, Rezvani N, Zakeri S, Gholami A, Babaeekhou L. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against *Plasmodium falciparum* merozoite surface protein-1 (42-kDa fragment) in BALB/c mice. *Medical Microbiology and Immunology*. 2018; 207: 151–166. <https://doi.org/10.1007/s00430-018-0535-4>.
- [58] Reisinger S, Khan D, Kong E, Berger A, Pollak A, Pollak DD.

- The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. *Pharmacology & Therapeutics*. 2015; 149: 213–226. <https://doi.org/10.1016/j.pharmthera.2015.01.001>.
- [59] Aksoy E, Zouain CS, Vanhoutte F, Fontaine J, Pavelka N, Thieblemont N, *et al*. Double-stranded RNAs from the helminth parasite *Schistosoma* activate TLR3 in dendritic cells. *The Journal of Biological Chemistry*. 2005; 280: 277–283. <https://doi.org/10.1074/jbc.M411223200>.
- [60] Chen D, Zhao Y, Feng Y, Jin C, Yang Q, Qiu H, *et al*. Expression of TLR2, TLR3, TLR4, and TLR7 on pulmonary lymphocytes of *Schistosoma japonicum*-infected C57BL/6 mice. *Innate Immunity*. 2019; 25: 224–234. <https://doi.org/10.1177/1753425919840424>.
- [61] Liu B, Liu Q, Yang L, Palaniappan SK, Bahar I, Thiagarajan PS, *et al*. Innate immune memory and homeostasis may be conferred through crosstalk between the TLR3 and TLR7 pathways. *Science Signaling*. 2016; 9: ra70. <https://doi.org/10.1126/scisignal.aac9340>.
- [62] Qi F, Wang D, Liu J, Zeng S, Xu L, Hu H, *et al*. Respiratory macrophages and dendritic cells mediate respiratory syncytial virus-induced IL-33 production in TLR3- or TLR7-dependent manner. *International Immunopharmacology*. 2015; 29: 408–415. <https://doi.org/10.1016/j.intimp.2015.10.022>.
- [63] Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. *Trends in Molecular Medicine*. 2007; 13: 460–469. <https://doi.org/10.1016/j.molmed.2007.09.002>.
- [64] Netea MG, van der Meer JWM. Trained Immunity: An Ancient Way of Remembering. *Cell Host & Microbe*. 2017; 21: 297–300. <https://doi.org/10.1016/j.chom.2017.02.003>.
- [65] Silberstein E, Chung CC, Debrabant A. The transcriptome landscape of 3D-cultured placental trophoblasts reveals activation of TLR2 and TLR3/7 in response to low *Trypanosoma cruzi* parasite exposure. *Frontiers in Microbiology*. 2023; 14: 1256385. <https://doi.org/10.3389/fmicb.2023.1256385>.
- [66] Chen JG, Du YT, Guan CH, Fan HY, Liu YA, Wang T, *et al*. Extracellular Vesicles Derived from *Plasmodium*-infected Hosts as Stimuli of “Trained” Innate Immunity. *Current Medicinal Chemistry*. 2023; 30: 4450–4465. <https://doi.org/10.2174/0929867330666230207115157>.
- [67] Qiu L, Ji H, Wang K, Liu W, Huang Q, Pan X, *et al*. TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. *EMBO Molecular Medicine*. 2024; 16: 1193–1219. <https://doi.org/10.1038/s44321-024-00068-4>.
- [68] Ju C, Ma Y, Zuo X, Wang X, Song Z, Zhang Z, *et al*. Photobiomodulation promotes spinal cord injury repair by inhibiting macrophage polarization through lncRNA TUG1-miR-1192/TLR3 axis. *Cellular & Molecular Biology Letters*. 2023; 28: 5. <https://doi.org/10.1186/s11658-023-00417-0>.
- [69] Zhang X, Li X, Gong P, Wang X, Zhang N, Chen M, *et al*. Host defense against *Neospora caninum* infection via IL-12p40 production through TLR2/TLR3-AKT-ERK signaling pathway in C57BL/6 mice. *Molecular Immunology*. 2021; 139: 140–152. <https://doi.org/10.1016/j.molimm.2021.08.019>.
- [70] Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, *et al*. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. *Nature Immunology*. 2003; 4: 491–496. <https://doi.org/10.1038/ni921>.
- [71] Peng YC, Wu J, He X, Dai J, Xia L, Valenzuela-Leon P, *et al*. NAD activates olfactory receptor 1386 to regulate type I interferon responses in *Plasmodium yoelii* YM infection. *Proceedings of the National Academy of Sciences of the United States of America*. 2024; 121: e2403796121. <https://doi.org/10.1073/pnas.2403796121>.
- [72] Huh HD, Lee E, Shin J, Park B, Lee S. STRAP positively regulates TLR3-triggered signaling pathway. *Cellular Immunology*. 2017; 318: 55–60. <https://doi.org/10.1016/j.cellimm.2017.06.005>.
- [73] Yang Q, Pröll MJ, Salilew-Wondim D, Zhang R, Tesfaye D, Fan H, *et al*. LPS-induced expression of CD14 in the TRIF pathway is epigenetically regulated by sulforaphane in porcine pulmonary alveolar macrophages. *Innate Immunity*. 2016; 22: 682–695. <https://doi.org/10.1177/1753425916669418>.
- [74] Xiao J, Li W, Zheng X, Qi L, Wang H, Zhang C, *et al*. Targeting 7-Dehydrocholesterol Reductase Integrates Cholesterol Metabolism and IRF3 Activation to Eliminate Infection. *Immunity*. 2020; 52: 109–122.e6. <https://doi.org/10.1016/j.immuni.2019.11.015>.
- [75] Wang L, Zhao J, Ren J, Hall KH, Moorman JP, Yao ZQ, *et al*. Protein phosphatase 1 abrogates IRF7-mediated type I IFN response in antiviral immunity. *European Journal of Immunology*. 2016; 46: 2409–2419. <https://doi.org/10.1002/eji.201646491>.
- [76] Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. *Genes & Diseases*. 2020; 8: 287–297. <https://doi.org/10.1016/j.gendis.2020.06.005>.
- [77] Zhu L, Lama S, Tu L, Disting GJ, Wang JH, Liu GS. TAK1 signaling is a potential therapeutic target for pathological angiogenesis. *Angiogenesis*. 2021; 24: 453–470. <https://doi.org/10.1007/s10456-021-09787-5>.
- [78] Sondergaard JN, Poghosyan S, Hontelez S, Louche P, Looman MWG, Ansems M, *et al*. DC-SCRIPT Regulates IL-10 Production in Human Dendritic Cells by Modulating NF-kBp65 Activation. *Journal of Immunology (Baltimore, Md.: 1950)*. 2015; 195: 1498–1505. <https://doi.org/10.4049/jimmunol.1402924>.
- [79] Han L, Zhuang MW, Deng J, Zheng Y, Zhang J, Nan ML, *et al*. SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways. *Journal of Medical Virology*. 2021; 93: 5376–5389. <https://doi.org/10.1002/jmv.27050>.
- [80] Li Q, Lv K, Jiang N, Liu T, Hou N, Yu L, *et al*. SOD3 suppresses early cellular immune responses to parasite infection. *Nature Communications*. 2024; 15: 4913. <https://doi.org/10.1038/s41467-024-49348-0>.
- [81] Chen Q, Fernandez V, Sundström A, Schlichtherle M, Datta S, Hagblom P, *et al*. Developmental selection of var gene expression in *Plasmodium falciparum*. *Nature*. 1998; 394: 392–395. <https://doi.org/10.1038/28660>.
- [82] Venkatesan P. The 2023 WHO World malaria report. *The Lancet. Microbe*. 2024; 5: e214. [https://doi.org/10.1016/S2666-5247\(24\)00016-8](https://doi.org/10.1016/S2666-5247(24)00016-8).
- [83] Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Malaria. *Lancet (London, England)*. 2023; 402: 2328–2345. [https://doi.org/10.1016/S0140-6736\(23\)01249-7](https://doi.org/10.1016/S0140-6736(23)01249-7).
- [84] Pamplona A, Silva-Santos B. $\gamma\delta$ T cells in malaria: a double-edged sword. *The FEBS Journal*. 2021; 288: 1118–1129. <https://doi.org/10.1111/febs.15494>.
- [85] Kumar R, Ng S, Engwerda C. The Role of IL-10 in Malaria: A Double Edged Sword. *Frontiers in Immunology*. 2019; 10: 229. <https://doi.org/10.3389/fimmu.2019.00229>.
- [86] Butler NS, Harris TH, Blader IJ. Regulation of immunopathogenesis during *Plasmodium* and *Toxoplasma* infections: more parallels than distinctions? *Trends in Parasitology*. 2013; 29: 593–602. <https://doi.org/10.1016/j.pt.2013.10.002>.
- [87] Good MF, Engwerda C. Defying malaria: Arming T cells to halt malaria. *Nature Medicine*. 2011; 17: 49–51. <https://doi.org/10.1038/nm0111-49>.
- [88] Soulard V, Roland J, Gorgette O, Barbier E, Cazenave PA, Pied S. An early burst of IFN-gamma induced by the pre-erythrocytic stage favours *Plasmodium yoelii* parasitaemia in

- B6 mice. *Malaria Journal*. 2009; 8: 128. <https://doi.org/10.1186/1475-2875-8-128>.
- [89] Souillard V, Roland J, Sellier C, Gruner AC, Leite-de-Moraes M, Franetich JF, *et al.* Primary infection of C57BL/6 mice with *Plasmodium yoelii* induces a heterogeneous response of NKT cells. *Infection and Immunity*. 2007; 75: 2511–2522. <https://doi.org/10.1128/IAI.01818-06>.
- [90] Qu J, Li L, Xie H, Zhang X, Yang Q, Qiu H, *et al.* TLR3 Modulates the Response of NK Cells against *Schistosoma japonicum*. *Journal of Immunology Research*. 2018; 2018: 7519856. <https://doi.org/10.1155/2018/7519856>.
- [91] Hsia BJ, Whitehead GS, Thomas SY, Nakano K, Gowdy KM, Aloor JJ, *et al.* Trif-dependent induction of Th17 immunity by lung dendritic cells. *Mucosal Immunology*. 2015; 8: 186–197. <https://doi.org/10.1038/mi.2014.56>.
- [92] Nuwangi H, Agampodi TC, Price HP, Shepherd T, Weerakoon KG, Agampodi SB. The stigma associated with cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL): A protocol for a systematic review. *PLoS One*. 2023; 18: e0285663. <https://doi.org/10.1371/journal.pone.0285663>.
- [93] Dantas-Torres F. Canine leishmaniasis in the Americas: etiology, distribution, and clinical and zoonotic importance. *Parasites & Vectors*. 2024; 17: 198. <https://doi.org/10.1186/s13071-024-06282-w>.
- [94] Arumugam S, Scorza BM, Petersen C. Visceral Leishmaniasis and the Skin: Dermal Parasite Transmission to Sand Flies. *Pathogens* (Basel, Switzerland). 2022; 11: 610. <https://doi.org/10.3390/pathogens11060610>.
- [95] Patidar A, Shukla D, Bodhale N, Saha B. TLR2, TLR3, TLR4, TLR9 and TLR11 expression on effector CD4⁺ T-cell subsets in *Leishmania donovani* infection. *Experimental Parasitology*. 2023; 255: 108645. <https://doi.org/10.1016/j.exppara.2023.108645>.
- [96] Kusakisako K, Nakao R, Katakura K. Detection of parasite-derived tRNA and rRNA fragments in the peripheral blood of mice experimentally infected with *Leishmania donovani* and *Leishmania amazonensis* using next-generation sequencing analysis. *Parasitology International*. 2023; 93: 102716. <https://doi.org/10.1016/j.parint.2022.102716>.
- [97] Sibley LD. Invasion and intracellular survival by protozoan parasites. *Immunological Reviews*. 2011; 240: 72–91. <https://doi.org/10.1111/j.1600-065X.2010.00990.x>.
- [98] Rossi M, Fasel N. How to master the host immune system? *Leishmania* parasites have the solutions!. *International Immunology*. 2018; 30: 103–111. <https://doi.org/10.1093/intimm/dxx075>.
- [99] Vivarini ADC, Pereira RDMS, Teixeira KLD, Calegari-Silva TC, Bellio M, Laurenti MD, *et al.* Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2. *FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology*. 2011; 25: 4162–4173. <https://doi.org/10.1096/fj.11-185165>.
- [100] Rodrigues FMD, Coelho Neto GT, Menezes JGPB, Gama MEA, Gonçalves EG, Silva AR, *et al.* Expression of Foxp3, TGF- β and IL-10 in American cutaneous leishmaniasis lesions. *Archives of Dermatological Research*. 2014; 306: 163–171. <https://doi.org/10.1007/s00403-013-1396-8>.
- [101] Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CEP. Immunopathogenic competences of *Leishmania* (V.) *braziliensis* and *L. (L.) amazonensis* in American cutaneous leishmaniasis. *Parasite Immunology*. 2009; 31: 423–431. <https://doi.org/10.1111/j.1365-3024.2009.01116.x>.
- [102] Eren RO, Reverte M, Rossi M, Hartley MA, Castiglioni P, Prevel F, *et al.* Mammalian Innate Immune Response to a *Leishmania*-Resident RNA Virus Increases Macrophage Survival to Promote Parasite Persistence. *Cell Host & Microbe*. 2016; 20: 318–328. <https://doi.org/10.1016/j.chom.2016.08.001>.
- [103] Alonazian R. Molecular regulation of NLRP3 inflammasome activation during parasitic infection. *Bioscience Reports*. 2024; 44: BSR20231918. <https://doi.org/10.1042/BSR20231918>.
- [104] de Carvalho RVH, Lima-Junior DS, da Silva MVG, Dilucca M, Rodrigues TS, Horta CV, *et al.* Publisher Correction: Leishmania RNA virus exacerbates Leishmaniasis by subverting innate immunity via TLR3-mediated NLRP3 inflammasome inhibition. *Nature Communications*. 2020; 11: 203. <https://doi.org/10.1038/s41467-019-13900-0>.
- [105] Kim TS, Pak JH, Kim JB, Bahk YY. Clonorchis sinensis, an oriental liver fluke, as a human biological agent of cholangiocarcinoma: a brief review. *BMB Reports*. 2016; 49: 590–597. <https://doi.org/10.5483/bmbrep.2016.49.11.109>.
- [106] Zhang Y, Gong QL, Lv QB, Qiu YY, Wang YC, Qiu HY, *et al.* Prevalence of Clonorchis sinensis infection in fish in South-East Asia: A systematic review and meta-analysis. *Journal of Fish Diseases*. 2020; 43: 1409–1418. <https://doi.org/10.1111/jfd.13245>.
- [107] Na BK, Pak JH, Hong SJ. Clonorchis sinensis and clonorchiasis. *Acta Tropica*. 2020; 203: 105309. <https://doi.org/10.1016/j.actatropica.2019.105309>.
- [108] Ge L, Chen D, Chen W, Cai C, Tao Y, Ye S, *et al.* Pre-activation of TLR3 enhances the therapeutic effect of BMMSCs through regulation of the intestinal HIF-2 α signaling pathway and balance of NKB cells in experimental alcoholic liver injury. *International Immunopharmacology*. 2019; 70: 477–485. <https://doi.org/10.1016/j.intimp.2019.02.021>.
- [109] Patole PS, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, *et al.* Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. *Journal of the American Society of Nephrology: JASN*. 2005; 16: 1326–1338. <https://doi.org/10.1681/ASN.2004100820>.
- [110] Zhang X, Duan S, Li X, Ding J, Zuo L, Sun B, *et al.* Differences in the secretory exosomes of Clonorchis sinensis adults at different incubation times. *Acta Tropica*. 2022; 234: 106604. <https://doi.org/10.1016/j.actatropica.2022.106604>.
- [111] Rao LZ, Wang Y, Zhang L, Wu G, Zhang L, Wang FX, *et al.* Correction: IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages. *Cell Death and Differentiation*. 2021; 28(10): 2989. <https://doi.org/10.1038/s41418-020-00721-8>.
- [112] Maranatha D, Hasan H, Bakhtiar A, Widyoningroem A, Aryati. Association of TNF- α , TGF- β 1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19. *Journal of Infection and Public Health*. 2022; 15: 1072–1075. <https://doi.org/10.1016/j.jiph.2022.08.007>.
- [113] Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. *Journal of Medical Virology*. 2022; 94: 869–877. <https://doi.org/10.1002/jmv.27405>.
- [114] Guo M, Wang Z, Dai J, Fan H, Yuan N, Gao L, *et al.* Glycyrrhizic acid alleviates liver fibrosis in vitro and in vivo via activating CUGBP1-mediated IFN- γ /STAT1/Smad7 pathway. *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology*. 2023; 112: 154587. <https://doi.org/10.1016/j.phymed.2022.154587>.
- [115] Okada C, Akbar SMF, Horiike N, Onji M. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. *Liver International: Official Journal of the International Association for the Study of the Liver*. 2005; 25: 595–603. <https://doi.org/10.1111/j.1478-3231.2005.01043.x>.

- [116] Calvo-Cano A, Cnops L, Huyse T, van Lieshout L, Pardos J, Valls ME, *et al.* A Case of Urogenital Human Schistosomiasis from a Non-endemic Area. *PLoS Neglected Tropical Diseases*. 2015; 9: e0004053. <https://doi.org/10.1371/journal.pntd.0004053>.
- [117] Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. *Acta Tropica*. 2000; 77: 41–51. [https://doi.org/10.1016/s0001-706x\(00\)00122-4](https://doi.org/10.1016/s0001-706x(00)00122-4).
- [118] Olveda RM, Gray DJ. Schistosomiasis in the Philippines: Innovative Control Approach is Needed if Elimination is the Goal. *Tropical Medicine and Infectious Disease*. 2019; 4: 66. <https://doi.org/10.3390/tropicalmed4020066>.
- [119] Li ZJ, Ge J, Dai JR, Wen LY, Lin DD, Madsen H, *et al.* Biology and Control of Snail Intermediate Host of *Schistosoma japonicum* in The People's Republic of China. *Advances in Parasitology*. 2016; 92: 197–236. <https://doi.org/10.1016/bs.apar.2016.02.003>.
- [120] Xu T, Chen J, Zhu D, Chen L, Wang J, Sun X, *et al.* Egg antigen p40 of *Schistosoma japonicum* promotes senescence in activated hepatic stellate cells via SKP2/P27 signaling pathway. *Scientific Reports*. 2017; 7: 275. <https://doi.org/10.1038/s41598-017-00326-1>.
- [121] Li L, Xie H, Wang M, Qu J, Cha H, Yang Q, *et al.* Characteristics of IL-9 induced by *Schistosoma japonicum* infection in C57BL/6 mouse liver. *Scientific Reports*. 2017; 7: 2343. <https://doi.org/10.1038/s41598-017-02422-8>.
- [122] McManus DP, Bergquist R, Cai P, Ranasinghe S, Tebeje BM, You H. Correction to: Schistosomiasis-from immunopathology to vaccines. *Seminars in Immunopathology*. 2020; 42(3): 373–374. <https://doi.org/10.1007/s00281-020-00789-x>.
- [123] Liu Z, Zhang L, Liang Y, Lu L. Pathology and molecular mechanisms of *Schistosoma japonicum*-associated liver fibrosis. *Frontiers in Cellular and Infection Microbiology*. 2022; 12: 1035765. <https://doi.org/10.3389/fcimb.2022.1035765>.
- [124] Cai P, Mu Y, Olveda RM, Ross AG, Olveda DU, McManus DP. Serum Exosomal miRNAs for Grading Hepatic Fibrosis Due to Schistosomiasis. *International Journal of Molecular Sciences*. 2020; 21: 3560. <https://doi.org/10.3390/ijms21103560>.
- [125] Echeverry DM, Santodomingo AMS, Thomas RS, González-Ugás J, Oyarzún-Ruiz P, Fuente MCSDL, *et al.* *Trichinella spiralis* in a cougar (*Puma concolor*) hunted by poachers in Chile. *Revista Brasileira De Parasitologia Veterinaria*. 2021; 30: e002821. <https://doi.org/10.1590/S1984-29612021033>.
- [126] Abou Hussien N, Faheem M, Sweed E, Ibrahim A. Ultrastructural tegumental changes of *Trichinella spiralis* adult and larval stages after in vitro exposure to *Allium sativum*. *Experimental Parasitology*. 2022; 239: 108314. <https://doi.org/10.1016/j.exppara.2022.108314>.
- [127] Qin Y, Ren Y, Yi C, Chileshe N, Chen Y, Zheng L, *et al.* Effect of Wortmannilactone F on *Trichinella spiralis* Enteral in Mice. *Vector Borne and Zoonotic Diseases (Larchmont, N.Y.)*. 2020; 20: 205–211. <https://doi.org/10.1089/vbz.2019.2482>.
- [128] Sun R, Ding J, Yang Y, Wu F, Wang X, Liu M, *et al.* *Trichinella spiralis* alleviates LPS-induced acute lung injury by modulating the protective Th2 immune response. *Veterinary Parasitology*. 2025; 333: 110206. <https://doi.org/10.1016/j.vetpar.2024.110206>.
- [129] Bien J, Cabaj W, Moskwa B. Recognition of antigens of three different stages of the *Trichinella spiralis* by antibodies from pigs infected with *T. spiralis*. *Experimental Parasitology*. 2013; 134: 129–137. <https://doi.org/10.1016/j.exppara.2013.02.007>.
- [130] Malone CJ, Oksanen A, Mukaratirwa S, Sharma R, Jenkins E. From wildlife to humans: The global distribution of *Trichinella* species and genotypes in wildlife and wildlife-associated human trichinellosis. *International Journal for Parasitology. Parasites and Wildlife*. 2024; 24: 100934. <https://doi.org/10.1016/j.ijppaw.2024.100934>.
- [131] Yu YR, Deng MJ, Lu WW, Jia MZ, Wu W, Qi YF. Systemic cytokine profiles and splenic toll-like receptor expression during *Trichinella spiralis* infection. *Experimental Parasitology*. 2013; 134: 92–101. <https://doi.org/10.1016/j.exppara.2013.02.014>.
- [132] Dowling JK, Mansell A. Toll-like receptors: the swiss army knife of immunity and vaccine development. *Clinical & Translational Immunology*. 2016; 5: e85. <https://doi.org/10.1038/cti.2016.22>.
- [133] Koerner J, Horvath D, Herrmann VL, MacKerracher A, Gander B, Yagita H, *et al.* PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. *Nature Communications*. 2021; 12: 2935. <https://doi.org/10.1038/s41467-021-23244-3>.
- [134] Brown A, Selkirk ME, Sarkies P. Identification of proteins that bind extracellular microRNAs secreted by the parasitic nematode *Trichinella spiralis*. *Biology Open*. 2023; 12: bio060096. <https://doi.org/10.1242/bio.060096>.
- [135] Donahoe SL, Lindsay SA, Krockenberger M, Phalen D, Šlapeta J. A review of neosporosis and pathologic findings of *Neospora caninum* infection in wildlife. *International Journal for Parasitology. Parasites and Wildlife*. 2015; 4: 216–238. <https://doi.org/10.1016/j.ijppaw.2015.04.002>.
- [136] Fereig RM, Nishikawa Y. From Signaling Pathways to Distinct Immune Responses: Key Factors for Establishing or Combating *Neospora caninum* Infection in Different Susceptible Hosts. *Pathogens (Basel, Switzerland)*. 2020; 9: 384. <https://doi.org/10.3390/pathogens9050384>.
- [137] Lindsay DS, Dubey JP. Neosporosis, Toxoplasmosis, and Sarcocystosis in Ruminants: An Update. *The Veterinary Clinics of North America. Food Animal Practice*. 2020; 36: 205–222. <https://doi.org/10.1016/j.cvfa.2019.11.004>.
- [138] Duarte PO, Oshiro LM, Zimmermann NP, Csordas BG, Dourado DM, Barros JC, *et al.* Serological and molecular detection of *Neospora caninum* and *Toxoplasma gondii* in human umbilical cord blood and placental tissue samples. *Scientific Reports*. 2020; 10: 9043. <https://doi.org/10.1038/s41598-020-65991-1>.
- [139] Zhao SS, Tao DL, Chen JM, Wu JP, Yang X, Song JK, *et al.* RNA sequencing reveals dynamic expression of lncRNAs and mRNAs in caprine endometrial epithelial cells induced by *Neospora caninum* infection. *Parasites & Vectors*. 2022; 15: 297. <https://doi.org/10.1186/s13071-022-05405-5>.
- [140] Li H, Li Q, Guo T, He W, Dong C, Wang Y. LncRNA CRNDE triggers inflammation through the TLR3-NF-κB-Cytokine signaling pathway. *Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine*. 2017; 39: 1010428317703821. <https://doi.org/10.1177/1010428317703821>.